Case Study: ThioBridge™ Conjugates

This case study explores Abzena’s ThioBridge™ conjugation technology, which employs a novel re-bridging mechanism to generate site-specific, highly stable, and homogeneous bioconjugates. Compared to traditional methods, ThioBridge offers significant advantages in conjugate stability and consistency. Abzena has optimized a scalable, GMP-compliant manufacturing process with high yields and purity, supporting multiple client programs. Several ThioBridge-based ADCs are currently in Phase 1 and 2 clinical trials, with demonstrated serum stability and proven efficacy.

The study highlights ThioBridge’s clinical relevance and its potential to advance next-generation antibody-drug conjugates.